Hercules Capital made this change in support of Motif Bio managing its cash runway as it advances its pipeline expansion strategy.
(LON:MTFB, NASDAQ:MTFB), the antibiotics developer, has amended its financing arrangement with Hercules Capital.
Hercules has agreed to amend the company's loan and security agreement by shifting back the next amortisation by one month to the first day of next month.
This change means that the August payment will be interest only.
"As we continue to evaluate options to build our pipeline, we are fortunate to have the support of our investors, who understand and appreciate the opportunities that may lay ahead,” said Graham Lumsden, the chief executive officer of Motif.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Motif Bio PLC named herein, including the promotion by the Company of Motif Bio PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE